Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15591826 | 0.82 | KDM4E (0.46) | SIGMAR1MC4R | |
| SCHEMBL15591792 | 0.79 | BMP4 (0.39) | SIGMAR1CYP1A2CYP3A4 | |
| SCHEMBL15591747 | 0.79 | ALDH1A1 (0.40) | SIGMAR1MC4R | |
| SCHEMBL2962759 | 0.79 | PIM1 (0.35) | — | |
| SCHEMBL15591823 | 0.78 | HTR7 (0.40) | SIGMAR1HTR6 | |
| SCHEMBL16477737 | 0.78 | CYP2C9 (0.37) | SIGMAR1CYP2D6CYP1A2HTR2AHTR2C | |
| SCHEMBL15591740 | 0.77 | HTR1A (0.42) | SIGMAR1MC4R | |
| SCHEMBL15591746 | 0.77 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL15591827 | 0.77 | ADRA1A (0.39) | SIGMAR1HTR2AHTR2C | |
| SCHEMBL2971821 | 0.76 | PIM1 (0.33) | SIGMAR1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493434-B2 | Substituted indenes as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-11-15 | — | — | US | disclosed |
| US-9493434-B2 | Substituted indenes as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-11-15 | — | — | US | disclosed |
| US-9493434-B2 | Substituted indenes as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-11-15 | — | — | US | disclosed |
| EP-2870145-B1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2016-09-21 | — | — | EP | disclosed |
| EP-2870145-B1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2016-09-21 | — | — | EP | disclosed |
| US-20150158831-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2015-06-11 | — | — | US | disclosed |
| US-20150158831-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2015-06-11 | — | — | US | disclosed |
| US-20150158831-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2015-06-11 | — | — | US | disclosed |
| EP-2870145-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014006071-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014006071-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-01-09 | — | — | WO | disclosed |
| EP-2682391-A1 | Indene derivatives, their preparation and use as medicaments | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-01-08 | — | — | EP | disclosed |
| EP-2682391-A1 | Indene derivatives, their preparation and use as medicaments | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158831-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885MC4R 1168/4885HTR6 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.